A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.
A 4-year Extension to a Phase II a Multicenter Study Evaluating Long-term Safety, Tolerability, Pharmacokinetics and Effects on Liver Iron Concentration of Repeated Doses of 10 mg/kg/Day of Deferasirox in Pediatric Patients With Transfusion Dependent β-thalassemia Major.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Completion of the planned 12-month core trial, (NCT00390858).
- Female patients who have reached menarche and who were sexually active were to use double-barrier contraception, oral contraceptive plus barrier contraceptive, or must have undergone clinically documented total hysterectomy and/or ovariectomy, or tubal ligation.
- Written informed consent obtained from the patient, and/or from the parent or legal guardian in accordance with the national legislation.
Exclusion Criteria:
- Pregnant or breast feeding patients
- Patients with a history of non-compliance to medical regimens and patients who are considered by the investigator as potentially unreliable.
Other protocol-defined exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Deferasirox
Initial dose of 10 mg/kg, dose modifications of ± 5 or 10 mg/kg were based on participant response.
|
Deferasirox in children from 1 to 18 years old was given orally once daily, 30 minutes prior to breakfast.
An initial daily dose of 10 mg/kg was used during the 1-year core study.
In this 4-year extension study dose modifications of ± 5 or 10 mg/kg were based on safety parameters and on increasing or decreasing Liver Iron Concentration (LIC), and serum ferritin.
Deferasirox was available as 125 mg, 250 mg and 500 mg tablets.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Participants With Adverse Events by Primary System Organ Class (SOC)
Time Frame: 4 year extension + core 1 year
|
Safety parameters were measured by the number and type of adverse events (AEs).
An adverse event is any untoward medical occurence in a patient administered a medicinal product that does not necessarily have a causal relationship with the treatment.
An adverse event can therefore be any unfavorable and unintended sign ( for example, an abnormal laboratory finding), symptom or disease temporally associated with the use of the medicinal product, whether or not this is associated with the use of this medicinal product.
|
4 year extension + core 1 year
|
|
Change in Liver Iron Concentration (LIC)
Time Frame: Baseline of Core Study to End of Extension Study, up to 5 years.
|
Change in Liver Iron Concentration [LIC] measured by means of SQUID (Superconducting Quantum Interference Device).
LIC is expressed in milligrams of iron per gram of liver dry weight (mg Fe/g dw)
|
Baseline of Core Study to End of Extension Study, up to 5 years.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total Body Iron Elimination (TBIE) Rate (mg/kg/Day)
Time Frame: Baseline of Core Study to End of Extension Study, up to 5 years
|
Total Iron Body Elimination (TBIE) Rate [mg/kg/Day] was calculated for each patient based on SQUID ( Superconducting Quantum Interference Device) results.
|
Baseline of Core Study to End of Extension Study, up to 5 years
|
|
Relative Change in Serum Ferritin Level
Time Frame: Baseline of Core Study to Extension 18 months, up to 2.5 years.
|
Serum levels were drawn at the baseline of the Core Study up to 18 months of the Extension Study.
Levels were analyzed for serum ferritin measured in micrograms per Liter.
Relative change (%) in serum ferritin level was assessed from Baseline to Extension 18 months.
Relative Change = 1 - (Change in ferritin level from Baseline/Baseline level) x 100.
|
Baseline of Core Study to Extension 18 months, up to 2.5 years.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Dr. Gianluca Forni, Novartis Pharmaceuticals
- Study Director: Prof. Renzo Galanello, Novartis Pharmaceuticals
- Study Director: Prof. Antonio Piga, Novartis Pharmaceuticals
- Study Director: Dr. Yves Bertrand, Novartis Pharmaceuticals
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Hematologic Diseases
- Genetic Diseases, Inborn
- Anemia
- Iron Metabolism Disorders
- Anemia, Hemolytic, Congenital
- Anemia, Hemolytic
- Hemoglobinopathies
- Iron Overload
- Thalassemia
- beta-Thalassemia
- Molecular Mechanisms of Pharmacological Action
- Chelating Agents
- Sequestering Agents
- Iron Chelating Agents
- Deferasirox
Other Study ID Numbers
Other Study ID Numbers
- CICL670A0106E1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.